David Durrant is a doctoral candidate in the Department of Biochemistry and Molecular Biology at the VCU School of Medicine. With guidance from Rakesh Kukreja, M.S., Ph.D., he is making significant progress testing a new combination therapy for pancreatic cancer, and many in the field of pharmacology are taking notice.
Cathy J. Bradley, Ph.D., has been appointed the associate director for cancer prevention and control at Virginia Commonwealth University Massey Cancer Center. Bradley transitions to this new role from her previous appointment as co-leader of the Cancer Prevention and Control research program at Massey.
Approximately 15 percent of all lung cancers are small cell lung cancers, which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.
Most people think of forests, parks or even city streets when they hear the word “environment,” but scientists define environment as everything outside the body that enters and interacts with the inside of the body. Some of these outside exposures have been linked to increased cancer risk.
Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. However, researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory experiments testing a new combination therapy that could potentially overcome the resistance hurdle.